Quote Request
Neuroendocrine Pancreatic Cancer
Neuroendocrine pancreatic cancer (NEPC) is a type of malignancy originating from the hormone-producing cells of the pancreas. With a focus on the intricacies of neuroendocrine tumor biology, Alfa Cytology is committed to advancing the field of pancreatic cancer research through innovative approaches and state-of-the-art technologies.
Overview of Neuroendocrine Pancreatic Cancer
NEPC is relatively rare, accounting for about 1-2% of all pancreatic cancers. These tumors are classified into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs), with varying degrees of malignancy. NEPC is characterized by the secretion of hormones such as insulin, gastrin, and glucagon, leading to a range of clinical syndromes depending on the hormone produced.
Fig. 1 Schematic of signaling pathways involved in pancreatic neuroendocrine tumor development and progression. (Shen X, et al, 2022)
While both NEPC and exocrine pancreatic cancer affect the pancreas, they differ significantly in their origin, genetic and molecular characteristics, clinical presentation, and treatment approaches. Unlike exocrine pancreatic cancer, which originates from the exocrine cells involved in digestive enzyme production, NEPCs exhibit distinct genetic and molecular profiles. Mechanistically, NEPC involves complex pathways including somatostatin receptor signaling, mTOR pathway alterations, and mutations in genes such as MEN1, DAXX, and ATRX.
Targets for Neuroendocrine Pancreatic Cancer Therapy Development
The following targets represent key pathways and mechanisms for the growth, survival, and progression of NEPC.
| Target | Importance |
|---|---|
| SSTRs | Frequently overexpressed in neuroendocrine tumors, making them prime targets for radiolabeled therapies and somatostatin analogs. |
| mTOR | Dysregulated mTOR signaling is common in NEPC, and its inhibition can reduce tumor growth. |
| VEGFR | Targeting VEGFR can inhibit blood supply to tumors, thereby restricting their growth. |
| PD-1 | Blocking PD-1 enhances the immune system's ability to attack cancer cells. |
| AKT | Inhibition of AKT can block downstream signaling that promotes tumor survival and proliferation. |
| JAK (Janus Kinase) | Targeting JAK can disrupt pathways that promote tumor growth and immune evasion. |
| Chromatin Remodeling Genes | Mutations in these genes are common in NEPC, providing a potential therapeutic target. |
| Notch Signaling Pathway | Aberrant Notch signaling is implicated in NEPC, making it a viable target for intervention. |
| c-MET | Overexpression and activation of c-MET are associated with poor prognosis in NEPC. |
| IGF-1R | Targeting IGF-1R can inhibit tumor cell proliferation and survival. |
| PDGFR | Inhibiting PDGFR can reduce tumor growth and angiogenesis. |
| Hedgehog Signaling Pathway | Dysregulated Hedgehog signaling is involved in the development and progression of NEPC. |
| GRP Receptors | Targeting GRP receptors can disrupt tumor growth and hormone secretion. |
Our Services
By leveraging advanced technology and a deep understanding of tumor biology, Alfa Cytology aims to provide researchers with a one-stop solution for neuroendocrine pancreatic cancer research. Our service encompasses a broad spectrum of activities, including disease modeling, therapeutic target identification, drug development, etc.
Basic Research Services for Neuroendocrine Pancreatic Cancer
Our researchers and biology experts can help you conduct basic research to uncover the molecular and cellular mechanisms that drive NEPC progression and drug resistance.
- Histopathological Analysis
- Molecular Pathology Studies
- Tumor Microenvironment Analysis
- Cell Line Establishment & Characterization
- Cell Analysis and Evaluation
- Cell Metabolism Research
- Microbiome Profiling
- Microbiota-Tumor Interactions
- Probiotic and Antimicrobial Interventions
NEPC-Associated Fibroblast Research
- Fibroblast Activation Studies
- CAF-Mediated Chemoresistance
- Fibroblast Signaling Pathways
- CSC Isolation and Characterization
- Induction of Cancer Cells to CSCs
- Detection & Identification of CSCs Intraperitoneal Inoculation
Customized Services
Basic research on NEPC, such as molecular mechanism, can be customized according to your needs.
Our Advanced Technology Platforms
Alfa Cytology's four main technology platforms are leading-edge, providing realistic in vitro and in vivo models for the precise study of NEPC, ensuring rigorous testing of therapeutic agents, as well as facilitating the optimization of novel targeted therapies.
Case Study - QGP-1 pNEC Xenograft Model
- Model Introduction
The subcutaneous QGP-1 xenograft model established in immunodeficient NMRI nude mice serves as a robust preclinical platform for evaluating novel therapeutic strategies against pancreatic neuroendocrine carcinoma (pNEC). This model effectively recapitulates the clinical progression and therapeutic resistance observed in human pNEC, enabling systematic assessment of both monotherapies and combination treatments in a clinically relevant context.
- Model Information
- Model: QGP-1 Xenograft Model
- Animal: NMRI Foxn1nu/Foxn1nu Mice
- Weight: 18-22 g
- Cell Line: QGP-1 Human Pancreatic Neuroendocrine Carcinoma Cell Line
- Cancer Type: Pancreatic Neuroendocrine Carcinoma (pNEC)
- Age: 6 Weeks
- Molecular Profile: High-grade neuroendocrine carcinoma (Ki-67 >20%, mitotic count >20/10 HPF)
- Model Construction
5 × 106 QGP-1 cells were suspended in Matrigel and implanted subcutaneously into both flank regions of NMRI nude mice. Tumor growth was monitored weekly using caliper measurements, and when tumor volumes reached approximately 200 mm3, mice were randomly allocated to various treatment groups for therapeutic evaluation.
Fig. 2 Workflow of QGP-1 xenograft model establishment and treatment. (Source: Alfa Cytology)
- In Vivo Efficacy Evaluation
This study utilized the established QGP-1 xenograft model to systematically evaluate the antitumor efficacy of Drug A, a GAPDH Inhibitor, and Chemotherapeutic Drug B as monotherapies and in combination.
- Monotherapy: Treatment with drug A alone demonstrated limited antitumor activity in the QGP-1 model, while treatment with drug B alone resulted in tumor stabilization. Compared to the untreated control group, drug B monotherapy achieved a modest but significant 20.9% ± 0.109 reduction in tumor volume.
- Combination Therapy: The combination of drug A and drug B demonstrated substantially enhanced anti-tumor efficacy. This combination therapy resulted in a 67.9% ± 0.061 reduction in tumor volume (p = 0.003 compared to drug B monotherapy).
Fig. 3 Anti-tumor activity of drug A in combination with drug B in QGP-1 xenograft model (n = 8). *p < 0.05, **p< 0.01,*** p ≤ 0.001. Data are presented as mean ± standard error (SEM). (Source: Alfa Cytology)
Alfa Cytology is a solution provider dedicated to helping our clients address key challenges encountered in the field of pancreatic cancer research. With expertise and cutting-edge technology, we are dedicated to PC cell research, PC stem cell (CSC) research, PC genetic/molecular research, PC biomarker discovery and analysis, PC modeling services, and more to meet the full spectrum of our clients' needs for basic PC research. For more details on how we help our clients identify new ways to improve study design and anticipate development challenges, please contact us.
Reference
- Shen X, et al. Molecular biology of pancreatic neuroendocrine tumors: From mechanism to translation. Front. Oncol. 2022, 12:967071.
